EUVIMEDEUVIMED entdecken
Crossref

Conjugating 4 β ‐NH‐(5‐Aminoindazole)‐podophyllotoxin and Galectin‐1‐Targeted Aptamer for Synergistic Chemo‐Immunotherapy of Hepatocellular Carcinoma

Ying Cong, Shu-Yue Zhang, Paula Yun-Zhi Tang, Hong-Mei Li, Xue Liu, Wei Zhao, Ya-Jie Tang iD

Advanced Healthcare Materials · 2023

DOI: 10.1002/adhm.202203144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Ying Cong und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

By conjugating a chemotherapeutic candidate drug 4 β ‐NH‐(5‐aminoindazole)‐podophyllotoxin ( β IZP) and an immunosuppressive protein galectin‐1 targeted aptamer AP74, a chemo‐immunotherapy molecule (AP74‐ β IZP) is developed against liver cancer. AP74‐ β IZP can target galectin‐1 and enrich the tumor microenvironment to improve the tumor inhibition ratio by 6.3%, higher than that of β IZP in a HepG2 xenograft model. In safety evaluation, β IZP cannot be released from AP74‐ β IZP in normal tissues with low glutathione level. Therefore, the degrees of organs injury and myelosuppression after the treatment with AP74‐ β IZP are lower than those with β IZP. After 21 d treatment at a drug dose of 5 mg kg −1 , AP74‐ β IZP does not cause weight loss in mice, while the weight is significantly reduced by 24% and 14% from oxaliplatin and β IZP, respectively. In immune synergy, AP74‐IZP enhances CD4/CD8 cell infiltration to promote the expression of cell factor (i.e., IL‐2, TNF‐ α , and IFN‐ γ ), which further improves the antitumor activity. The tumor inhibition ratio of AP74‐ β IZP is 70.2%, which is higher than that of AP74 (35.2%) and β IZP (48.8%). Because of the dual effects of chemotherapy and immunotherapy, AP74‐ β IZP exhibits superior activity and lower toxicity. The approach developed in this work could be applicable to other chemotherapy drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansAnimalsMicePodophyllotoxinGalectin 1ImmunotherapyTumor MicroenvironmentIndazoles

Stichwörter der Autor:innen

4β-NH-(5-aminoindazole)-podophyllotoxinaptamerschemo-immunotherapygalectin-1immune infiltration

Substanzen

PodophyllotoxinGalectin 15-aminoindazoleIndazoles

Autor:innen und Institutionen

  • State Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
  • China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, 300457, China.
  • Jinan Zhensheng School, Jinan, 250102, China.
  • Jinan Food and Drug Inspection and Testing Center, Jinan, 250101, China.

ORCID-Profile: Ya-Jie Tang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cong, Y., Zhang, S. Y., Tang, P. Y., Li, H. M., Liu, X., Zhao, W., & Tang, Y. J. (2023). Conjugating 4 β ‐NH‐(5‐Aminoindazole)‐podophyllotoxin and Galectin‐1‐Targeted Aptamer for Synergistic Chemo‐Immunotherapy of Hepatocellular Carcinoma. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202203144

Vancouver

Cong Y, Zhang SY, Tang PY, Li HM, Liu X, Zhao W, et al. Conjugating 4 β ‐NH‐(5‐Aminoindazole)‐podophyllotoxin and Galectin‐1‐Targeted Aptamer for Synergistic Chemo‐Immunotherapy of Hepatocellular Carcinoma. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202203144

BibTeX
@article{Cong2023,
  author = {Cong, Ying and Zhang, Shu-Yue and Tang, Paula Yun-Zhi and Li, Hong-Mei and Liu, Xue and Zhao, Wei and Tang, Ya-Jie},
  title = {Conjugating 4 β ‐NH‐(5‐Aminoindazole)‐podophyllotoxin and Galectin‐1‐Targeted Aptamer for Synergistic Chemo‐Immunotherapy of Hepatocellular Carcinoma},
  journal = {Advanced Healthcare Materials},
  year = {2023},
  doi = {10.1002/adhm.202203144}
}
Kostenlos starten →